| 001 | 182798 | ||
| 005 | 20240229145731.0 | ||
| 024 | 7 | _ | |a 10.3390/cancers14225499 |2 doi |
| 024 | 7 | _ | |a pmid:36428592 |2 pmid |
| 024 | 7 | _ | |a altmetric:138208990 |2 altmetric |
| 037 | _ | _ | |a DKFZ-2022-02930 |
| 041 | _ | _ | |a English |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Pham, Thu-Thi |0 0000-0002-2129-0911 |b 0 |
| 245 | _ | _ | |a Pre-Diagnostic Circulating Resistin Concentrations Are Not Associated with Colorectal Cancer Risk in the European Prospective Investigation into Cancer and Nutrition Study. |
| 260 | _ | _ | |a Basel |c 2022 |b MDPI |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1669637970_24552 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 520 | _ | _ | |a Resistin is a polypeptide implicated in inflammatory processes, and as such could be linked to colorectal carcinogenesis. In case-control studies, higher resistin levels have been found in colorectal cancer (CRC) patients compared to healthy individuals. However, evidence for the association between pre-diagnostic resistin and CRC risk is scarce. We investigated pre-diagnostic resistin concentrations and CRC risk within the European Prospective Investigation into Cancer and Nutrition using a nested case-control study among 1293 incident CRC-diagnosed cases and 1293 incidence density-matched controls. Conditional logistic regression models controlled for matching factors (age, sex, study center, fasting status, and women-related factors in women) and potential confounders (education, dietary and lifestyle factors, body mass index (BMI), BMI-adjusted waist circumference residuals) were used to estimate relative risks (RRs) and 95% confidence intervals (CIs) for CRC. Higher circulating resistin concentrations were not associated with CRC (RR per doubling resistin, 1.11; 95% CI 0.94-1.30; p = 0.22). There were also no associations with CRC subgroups defined by tumor subsite or sex. However, resistin was marginally associated with a higher CRC risk among participants followed-up maximally two years, but not among those followed-up after more than two years. We observed no substantial correlation between baseline circulating resistin concentrations and adiposity measures (BMI, waist circumference), adipokines (adiponectin, leptin), or metabolic and inflammatory biomarkers (C-reactive protein, C-peptide, high-density lipoprotein cholesterol, reactive oxygen metabolites) among controls. In this large-scale prospective cohort, there was little evidence of an association between baseline circulating resistin concentrations and CRC risk in European men and women. |
| 536 | _ | _ | |a 313 - Krebsrisikofaktoren und Prävention (POF4-313) |0 G:(DE-HGF)POF4-313 |c POF4-313 |f POF IV |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de |
| 650 | _ | 7 | |a colorectal cancer |2 Other |
| 650 | _ | 7 | |a inflammation |2 Other |
| 650 | _ | 7 | |a pre-diagnostic resistin |2 Other |
| 650 | _ | 7 | |a prospective |2 Other |
| 650 | _ | 7 | |a risk |2 Other |
| 700 | 1 | _ | |a Nimptsch, Katharina |b 1 |
| 700 | 1 | _ | |a Aleksandrova, Krasimira |b 2 |
| 700 | 1 | _ | |a Jenab, Mazda |0 0000-0002-0573-1852 |b 3 |
| 700 | 1 | _ | |a Reichmann, Robin |b 4 |
| 700 | 1 | _ | |a Wu, Kana |b 5 |
| 700 | 1 | _ | |a Tjønneland, Anne |0 0000-0003-4385-2097 |b 6 |
| 700 | 1 | _ | |a Kyrø, Cecilie |0 0000-0002-9083-8960 |b 7 |
| 700 | 1 | _ | |a Schulze, Matthias B |0 0000-0002-0830-5277 |b 8 |
| 700 | 1 | _ | |a Kaaks, Rudolf |0 P:(DE-He78)4b2dc91c9d1ac33a1c0e0777d0c1697a |b 9 |u dkfz |
| 700 | 1 | _ | |a Katzke, Verena |0 P:(DE-He78)fb68a9386399d72d84f7f34cfc6048b4 |b 10 |u dkfz |
| 700 | 1 | _ | |a Palli, Domenico |0 0000-0002-5558-2437 |b 11 |
| 700 | 1 | _ | |a Pasanisi, Fabrizio |0 0000-0003-4224-7821 |b 12 |
| 700 | 1 | _ | |a Ricceri, Fulvio |0 0000-0001-8749-9737 |b 13 |
| 700 | 1 | _ | |a Tumino, Rosario |b 14 |
| 700 | 1 | _ | |a Krogh, Vittorio |0 0000-0003-0122-8624 |b 15 |
| 700 | 1 | _ | |a Roodhart, Jeanine |b 16 |
| 700 | 1 | _ | |a Castilla, Jesús |0 0000-0002-6396-7265 |b 17 |
| 700 | 1 | _ | |a Sánchez, Maria-Jose |0 0000-0003-4817-0757 |b 18 |
| 700 | 1 | _ | |a Colorado-Yohar, Sandra Milena |0 0000-0002-6700-0780 |b 19 |
| 700 | 1 | _ | |a Harbs, Justin |b 20 |
| 700 | 1 | _ | |a Rutegård, Martin |0 0000-0002-0974-6373 |b 21 |
| 700 | 1 | _ | |a Papier, Keren |0 0000-0002-4102-6835 |b 22 |
| 700 | 1 | _ | |a Aglago, Elom K |0 0000-0002-0442-3284 |b 23 |
| 700 | 1 | _ | |a Dimou, Niki |b 24 |
| 700 | 1 | _ | |a Mayen-Chacon, Ana-Lucia |b 25 |
| 700 | 1 | _ | |a Weiderpass, Elisabete |0 0000-0003-2237-0128 |b 26 |
| 700 | 1 | _ | |a Pischon, Tobias |0 0000-0003-1568-767X |b 27 |
| 773 | _ | _ | |a 10.3390/cancers14225499 |g Vol. 14, no. 22, p. 5499 - |0 PERI:(DE-600)2527080-1 |n 22 |p 5499 |t Cancers |v 14 |y 2022 |x 2072-6694 |
| 909 | C | O | |o oai:inrepo02.dkfz.de:182798 |p VDB |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 9 |6 P:(DE-He78)4b2dc91c9d1ac33a1c0e0777d0c1697a |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 10 |6 P:(DE-He78)fb68a9386399d72d84f7f34cfc6048b4 |
| 913 | 1 | _ | |a DE-HGF |b Gesundheit |l Krebsforschung |1 G:(DE-HGF)POF4-310 |0 G:(DE-HGF)POF4-313 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-300 |4 G:(DE-HGF)POF |v Krebsrisikofaktoren und Prävention |x 0 |
| 914 | 1 | _ | |y 2022 |
| 915 | _ | _ | |a Creative Commons Attribution CC BY (No Version) |0 LIC:(DE-HGF)CCBYNV |2 V:(DE-HGF) |b DOAJ |d 2021-05-04 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0160 |2 StatID |b Essential Science Indicators |d 2021-05-04 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1190 |2 StatID |b Biological Abstracts |d 2021-05-04 |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0113 |2 StatID |b Science Citation Index Expanded |d 2021-05-04 |
| 915 | _ | _ | |a Article Processing Charges |0 StatID:(DE-HGF)0561 |2 StatID |d 2021-05-04 |
| 915 | _ | _ | |a Fees |0 StatID:(DE-HGF)0700 |2 StatID |d 2021-05-04 |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b CANCERS : 2021 |d 2022-11-30 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2022-11-30 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2022-11-30 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0501 |2 StatID |b DOAJ Seal |d 2022-01-24T07:56:58Z |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0500 |2 StatID |b DOAJ |d 2022-01-24T07:56:58Z |
| 915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b DOAJ : Blind peer review |d 2022-01-24T07:56:58Z |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0600 |2 StatID |b Ebsco Academic Search |d 2022-11-30 |
| 915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b ASC |d 2022-11-30 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2022-11-30 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2022-11-30 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1050 |2 StatID |b BIOSIS Previews |d 2022-11-30 |
| 915 | _ | _ | |a IF >= 5 |0 StatID:(DE-HGF)9905 |2 StatID |b CANCERS : 2021 |d 2022-11-30 |
| 920 | 1 | _ | |0 I:(DE-He78)C020-20160331 |k C020 |l C020 Epidemiologie von Krebs |x 0 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a I:(DE-He78)C020-20160331 |
| 980 | _ | _ | |a UNRESTRICTED |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|
guest ::